DOMESCO Medical Import Export JSC (DMC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DOMESCO Medical Import Export JSC stock VND 68,811, price VND 52,900, upside +30.1%, quality 67 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 37,232 VND – 83,000 VND · fair‑value band 42,378 VND – 102,745 VND · the 52,900 VND price screens below the 68,811 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow DOMESCO Medical Import Export JSC in your weekly email
Every Wednesday you see whether DOMESCO Medical Import Export JSC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Domesco Medical Import - Export Joint-Stock Corporation engages in the research and development, manufacturing, marketing, and trading of pharmaceutical materials, functional food, pure drinking water and medical beverages in Vietnam.
Show moreShow less
The company is also involved in the import and export of medicines, medicine materials, food-functional food, medical supplies, and medical equipment.
It provides herbal, food, dietary supplement, and anti-epidermic products, as well as synthetic drug products such as, cardiovascular agents; antidiabetics; antibiotics; analgesics and antipyretic drugs; respiratory agents; gastrointestinal drugs; minerals and vitamins; and other synthetic drug products.
The company offers its products under the Domesco brand name. The company was founded in 1989 and is headquartered in Cao Lãnh, Vietnam. Domesco Medical Import - Export Joint-Stock Corporation is a subsidiary of Abbott Laboratories(Chile) Holdco SpA.
Stock analysis
DOMESCO Medical Import Export JSC (DMC) currently trades at 52,900 VND, while our model-based Fair Value estimate is 68,811 VND, implying the stock looks roughly 23% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 98,062 VND per share, and 15 of the 26 models we run sit above the 52,900 VND price.
Bear case: the Dividend Discount group reads lowest at 22,872 VND, and 11 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 42,378 VND (bear) to 102,745 VND (bull), the price of 52,900 VND sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
DOMESCO Medical Import Export JSC reported revenue of 2.1T VND in FY2025 versus 1.5T VND in FY2021, a compound +8.4%/yr. Reported net income was 198B VND in FY2025, compounding +5.6%/yr from FY2021.
Key figures
Market cap 1.8T VND (≈ $71.8M) Micro · P/E ratio 9.3 · P/S ratio 0.86 · EPS (TTM) 5,682 VND · Dividend yield 4.5% · Net margin 10.8% · Return on equity 14.1% · Return on assets (EBIT) 11.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 30%, DMC screens cheaper than that median.
Fair Value models
Bear42,378 VNDFair Value 68,811 VNDBull102,745 VND
Price 52,900 VND · Upside +30.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (4,857 VND per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in VND ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in VND: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.0%
Dividend (yield on the price)4.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 11%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Vietnam: IMF forecast 4.1% a year to 2030, 3.1% from 2016 to 2025) that is about +9.4% a year for the price.
Compare DOMESCO Medical Import Export JSC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+30.1% · Top 25%
Profitability
Return on equity (12 months)14.1% · Top 25%
Return on assets10.4% · Top 25%
Net margin (12 months)10.8% · Above median
Operating margin (12 months)11.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)1.7% · Below median
Dividend yield (12 months)4.5% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)9.3× · Cheapest 25%
P/B1.09× · Cheaper than median
P/S (12 months)0.86× · Cheapest 25%
Price / free cash flow (fiscal year)14.7× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DOMESCO Medical Import Export JSC Fair Value". https://www.fairvalue-calculator.com/stock/DMC
Frequently asked questions
Is DOMESCO Medical Import Export JSC (DMC) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 68,811 VND versus a price of 52,900 VND, about +30% upside (undervalued).
What is the fair value of DMC?
Our model-based fair value for DOMESCO Medical Import Export JSC is 68,811 VND (as of Nov 5, 2026), built from audited fundamentals. The current price: 52,900 VND.
What is the quality score of DMC?
DOMESCO Medical Import Export JSC has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DOMESCO Medical Import Export JSC (DMC)?
Our model-based price target is the fair value of 68,811 VND (as of Nov 5, 2026) from 26 valuation models. Cautious scenario 42,378 VND, optimistic scenario 102,745 VND. It is a calculation from audited fundamentals, not an analyst target.
What is the DOMESCO Medical Import Export JSC stock forecast for 2026?
Our models put fair value at 68,811 VND, about +30% upside versus a price of 52,900 VND (undervalued). Cautious scenario 42,378 VND, optimistic scenario 102,745 VND. The calculation is refreshed regularly with new filings.
What is the revenue of DOMESCO Medical Import Export JSC (DMC)?
DOMESCO Medical Import Export JSC reported trailing-twelve-month revenue of about 2.1T VND (latest available figure, as of Nov 5, 2026).
Does DOMESCO Medical Import Export JSC pay a dividend?
DOMESCO Medical Import Export JSC currently shows a dividend yield of 4.48% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of DOMESCO Medical Import Export JSC (DMC)?
DOMESCO Medical Import Export JSC has a dividend yield of 4.5%.
What growth is priced into DOMESCO Medical Import Export JSC (DMC)?
For today's price to be fair in a discounted-cash-flow model, DOMESCO Medical Import Export JSC would have to grow free cash flow by +13.9 % per year for five years (discount rate 14.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of DMC use?
Our models discount DOMESCO Medical Import Export JSC at 14.9 %: a base by market capitalisation (micro), damped by beta 0.13, country premium for Vietnam. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DOMESCO Medical Import Export JSC that is +13.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (14.9 %) and the same formula as our fair value.
How much growth has DOMESCO Medical Import Export JSC (DMC) delivered so far?
Over the past 5 years revenue at DOMESCO Medical Import Export JSC grew +7.3 % a year. The price currently implies free-cash-flow growth of +13.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DOMESCO Medical Import Export JSC (DMC) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into DOMESCO Medical Import Export JSC (+13.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DOMESCO Medical Import Export JSC (DMC)?
The free-cash-flow yield on the price is 6.79 %: that much free cash flow DOMESCO Medical Import Export JSC produces per unit of market value. When it exceeds the discount rate of our models (14.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DOMESCO Medical Import Export JSC (DMC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DOMESCO Medical Import Export JSC it is 68,811 VND per share (as of Nov 5, 2026), against a price of 52,900 VND. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DOMESCO Medical Import Export JSC stock overvalued or undervalued in 2026?
As of Nov 5, 2026, DMC trades below its calculated fair value: price 52,900 VND, fair value 68,811 VND, a gap of about +30% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DMC?
No. The price is what the market pays today (52,900 VND); the fair value is what the company's own numbers justify (68,811 VND). For DOMESCO Medical Import Export JSC the two are 15,911 VND per share apart. That gap is exactly why we show both numbers side by side.
How much is DOMESCO Medical Import Export JSC worth?
The market values DOMESCO Medical Import Export JSC at about 1.8T VND (market capitalisation, as of Nov 5, 2026). Per share that is 52,900 VND; our models calculate a fair value of 68,811 VND per share.
What do the bullish and bearish scenarios say about DMC?
Our models span a range for DOMESCO Medical Import Export JSC: cautious scenario 42,378 VND, base 68,811 VND, optimistic 102,745 VND per share (as of Nov 5, 2026, price 52,900 VND). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DMC?
DOMESCO Medical Import Export JSC trades at a price-to-earnings ratio of 9.3 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 68,811 VND is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 10.5. Other multiples: P/B 1.1, P/S 0.9, EV/EBITDA 6.5.
How solid is the balance sheet of DOMESCO Medical Import Export JSC (DMC)?
Balance-sheet figures for DOMESCO Medical Import Export JSC (as of Nov 5, 2026): return on equity 14.1%. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is DMC from its 52-week high?
DOMESCO Medical Import Export JSC trades at 52,900 VND, about 16% below its 52-week high of 63,000 VND and at the low of 52,900 VND (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 68,811 VND is for.
Which stocks are comparable to DOMESCO Medical Import Export JSC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DOMESCO Medical Import Export JSC stock attractive at the current price?
The data as of Nov 5, 2026: price 52,900 VND, calculated fair value 68,811 VND (+30%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DMC calculated?
We run DOMESCO Medical Import Export JSC through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 68,811 VND builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. DOMESCO Medical Import Export JSC currently trades 23% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DOMESCO Medical Import Export JSC (DMC)?
The closing price on Nov 6, 2026 was 52,900 VND. Our model-based fair value is 68,811 VND, about +30% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DOMESCO Medical Import Export JSC right now?
Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (42,378 VND to 102,745 VND) leaves room in how you read the outcome.
Key figures of DOMESCO Medical Import Export JSC
How large is the market capitalisation of DOMESCO Medical Import Export JSC (DMC)?
The market capitalisation of DOMESCO Medical Import Export JSC is 1.8T VND (≈ $71.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DOMESCO Medical Import Export JSC (DMC)?
The price-to-sales ratio of DOMESCO Medical Import Export JSC is 0.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DOMESCO Medical Import Export JSC (DMC)?
Earnings per share at DOMESCO Medical Import Export JSC are 5,682 VND (price ÷ EPS = P/E 9.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DOMESCO Medical Import Export JSC (DMC)?
The dividend yield of DOMESCO Medical Import Export JSC is 4.5% (payout 41.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DOMESCO Medical Import Export JSC (DMC)?
The net margin of DOMESCO Medical Import Export JSC is 10.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DOMESCO Medical Import Export JSC (DMC)?
The return on equity (ROE) of DOMESCO Medical Import Export JSC is 14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DOMESCO Medical Import Export JSC (DMC)?
On an EBIT basis the return on assets of DOMESCO Medical Import Export JSC is 11.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DOMESCO Medical Import Export JSC (DMC)?
The operating margin of DOMESCO Medical Import Export JSC is 11.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DOMESCO Medical Import Export JSC (DMC)?
Revenue at DOMESCO Medical Import Export JSC is growing +1.7% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DOMESCO Medical Import Export JSC (DMC)?
Earnings per share at DOMESCO Medical Import Export JSC are growing +78.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch DOMESCO Medical Import Export JSC in the live analysis
One click puts DOMESCO Medical Import Export JSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026